Birdwatch Note
2024-08-09 15:47:54 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
中村篤史は患者に何も治療をしておらず、ワクチンが原因とする根拠も示していません https://megalodon.jp/2024-0810-0040-50/https://note.com:443/nakamuraclinic/n/nb1b340a7d697 ユーイング肉腫は小児に発生する骨腫瘍では骨肉腫に次いで2番目に多く、5年生存率は30%以下です https://ganjoho.jp/public/cancer/Ewing_sarcoma/about.html https://www.cochrane.org/ja/CD011405/CHILDCA_zhen-duan-shi-nizhuan-yi-xing-yuingurou-zhong-garen-meraretaxiao-er-si-chun-qi-oyobiruo-nian-cheng 現在の主流のがん治療は劇的に進歩しています https://news.yahoo.co.jp/expert/articles/1b191a2ed5889e97d4311826f130aa016629b2a8 https://doi.org/10.1016/j.ejca.2017.01.035 年齢調整死亡率で日本はG7の中でも最も優秀です https://data.oecd.org/chart/7hLT https://data.oecd.org/healthstat/deaths-from-cancer.htm 科学的根拠に基づかない主張の目的は偽医療への誘導です。 日本人が欧米事情等に疎いことは昔から偽医療利権に悪用されています https://youtu.be/nySPY7eH9IU https://cancer.jpn.org/static/fake_medicine.html https://cancer.jpn.org/static/ota_h_405_unconventional_cancer_treatments.html 病院に内緒で飲んだとされるアサイゲルマの効果や安全性は未証明で、腎臓や肝臓の障害などが発生する恐れがあります https://hfnet.nibiohn.go.jp/column/detail979/
Written by EE7192EF0B1C47D8A3430C3E070DA2A0BFAA58717F9133404318E9D7666B1A00
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1821916792044056939
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1821936451099181232
- noteId - 1821936451099181232
- participantId -
- noteAuthorParticipantId - EE7192EF0B1C47D8A3430C3E070DA2A0BFAA58717F9133404318E9D7666B1A00 Participant Details
- createdAtMillis - 1723218474541
- tweetId - 1821916792044056939
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- 中村篤史は患者に何も治療をしておらず、ワクチンが原因とする根拠も示していません https://megalodon.jp/2024-0810-0040-50/https://note.com:443/nakamuraclinic/n/nb1b340a7d697 ユーイング肉腫は小児に発生する骨腫瘍では骨肉腫に次いで2番目に多く、5年生存率は30%以下です https://ganjoho.jp/public/cancer/Ewing_sarcoma/about.html https://www.cochrane.org/ja/CD011405/CHILDCA_zhen-duan-shi-nizhuan-yi-xing-yuingurou-zhong-garen-meraretaxiao-er-si-chun-qi-oyobiruo-nian-cheng 現在の主流のがん治療は劇的に進歩しています https://news.yahoo.co.jp/expert/articles/1b191a2ed5889e97d4311826f130aa016629b2a8 https://doi.org/10.1016/j.ejca.2017.01.035 年齢調整死亡率で日本はG7の中でも最も優秀です https://data.oecd.org/chart/7hLT https://data.oecd.org/healthstat/deaths-from-cancer.htm 科学的根拠に基づかない主張の目的は偽医療への誘導です。 日本人が欧米事情等に疎いことは昔から偽医療利権に悪用されています https://youtu.be/nySPY7eH9IU https://cancer.jpn.org/static/fake_medicine.html https://cancer.jpn.org/static/ota_h_405_unconventional_cancer_treatments.html 病院に内緒で飲んだとされるアサイゲルマの効果や安全性は未証明で、腎臓や肝臓の障害などが発生する恐れがあります https://hfnet.nibiohn.go.jp/column/detail979/
Note Ratings
rated at | rated by | |
2024-08-21 18:47:52 -0500 | Rating Details | |
2024-08-21 16:57:16 -0500 | Rating Details | |
2024-08-21 08:29:07 -0500 | Rating Details | |
2024-08-21 07:58:55 -0500 | Rating Details | |
2024-08-17 06:25:09 -0500 | Rating Details | |
2024-08-16 05:46:30 -0500 | Rating Details | |
2024-08-13 22:59:48 -0500 | Rating Details | |
2024-08-13 15:02:18 -0500 | Rating Details | |
2024-08-13 06:58:09 -0500 | Rating Details | |
2024-08-13 04:14:20 -0500 | Rating Details | |
2024-08-11 10:56:08 -0500 | Rating Details | |
2024-08-11 08:31:36 -0500 | Rating Details | |
2024-08-11 08:15:21 -0500 | Rating Details | |
2024-08-11 06:34:06 -0500 | Rating Details | |
2024-08-11 04:42:59 -0500 | Rating Details | |
2024-08-10 20:27:38 -0500 | Rating Details | |
2024-08-10 18:12:16 -0500 | Rating Details | |
2024-08-10 16:59:56 -0500 | Rating Details | |
2024-08-10 11:49:51 -0500 | Rating Details | |
2024-08-10 11:20:02 -0500 | Rating Details | |
2024-08-10 08:49:47 -0500 | Rating Details | |
2024-08-10 08:29:21 -0500 | Rating Details | |
2024-08-10 08:12:01 -0500 | Rating Details | |
2024-08-10 07:07:42 -0500 | Rating Details | |
2024-08-10 05:59:27 -0500 | Rating Details | |
2024-08-10 05:48:50 -0500 | Rating Details | |
2024-08-10 05:20:06 -0500 | Rating Details | |
2024-08-10 05:10:54 -0500 | Rating Details | |
2024-08-10 05:04:40 -0500 | Rating Details | |
2024-08-10 04:35:37 -0500 | Rating Details | |
2024-08-10 04:34:44 -0500 | Rating Details | |
2024-08-10 04:30:20 -0500 | Rating Details | |
2024-08-10 04:22:25 -0500 | Rating Details | |
2024-08-10 04:19:10 -0500 | Rating Details | |
2024-08-10 04:17:04 -0500 | Rating Details | |
2024-08-10 04:16:00 -0500 | Rating Details | |
2024-08-10 04:10:27 -0500 | Rating Details | |
2024-08-10 04:09:52 -0500 | Rating Details | |
2024-08-10 04:08:22 -0500 | Rating Details | |
2024-08-10 04:07:55 -0500 | Rating Details | |
2024-08-10 04:06:05 -0500 | Rating Details | |
2024-08-10 03:53:14 -0500 | Rating Details | |
2024-08-10 02:35:19 -0500 | Rating Details | |
2024-08-10 02:34:21 -0500 | Rating Details | |
2024-08-10 01:17:08 -0500 | Rating Details | |
2024-08-10 01:13:33 -0500 | Rating Details | |
2024-08-10 00:31:27 -0500 | Rating Details | |
2024-08-10 00:06:33 -0500 | Rating Details | |
2024-08-09 23:46:10 -0500 | Rating Details | |
2024-08-09 23:29:31 -0500 | Rating Details | |
2024-08-09 23:11:22 -0500 | Rating Details | |
2024-08-09 22:53:10 -0500 | Rating Details | |
2024-08-09 22:00:56 -0500 | Rating Details | |
2024-08-09 20:15:55 -0500 | Rating Details | |
2024-08-09 20:09:50 -0500 | Rating Details | |
2024-08-09 19:42:47 -0500 | Rating Details | |
2024-08-09 19:39:25 -0500 | Rating Details | |
2024-08-09 19:37:10 -0500 | Rating Details | |
2024-08-09 19:22:09 -0500 | Rating Details | |
2024-08-09 17:57:52 -0500 | Rating Details | |
2024-08-09 17:56:28 -0500 | Rating Details | |
2024-08-09 17:41:55 -0500 | Rating Details | |
2024-08-09 17:39:24 -0500 | Rating Details | |
2024-08-09 17:37:29 -0500 | Rating Details | |
2024-08-09 17:36:47 -0500 | Rating Details | |
2024-08-09 17:32:32 -0500 | Rating Details | |
2024-08-09 17:20:22 -0500 | Rating Details | |
2024-08-09 17:09:55 -0500 | Rating Details | |
2024-08-09 17:04:42 -0500 | Rating Details | |
2024-08-09 16:50:15 -0500 | Rating Details | |
2024-08-09 16:45:35 -0500 | Rating Details | |
2024-08-09 16:26:11 -0500 | Rating Details | |
2024-08-09 16:20:29 -0500 | Rating Details | |
2024-08-09 15:33:05 -0500 | Rating Details | |
2024-08-09 15:21:33 -0500 | Rating Details | |
2024-08-09 15:14:25 -0500 | Rating Details | |
2024-08-09 15:10:34 -0500 | Rating Details | |
2024-08-09 15:02:22 -0500 | Rating Details | |
2024-08-09 15:01:37 -0500 | Rating Details | |
2024-08-09 14:55:07 -0500 | Rating Details | |
2024-08-09 14:51:45 -0500 | Rating Details | |
2024-08-09 14:38:06 -0500 | Rating Details | |
2024-08-09 14:34:48 -0500 | Rating Details | |
2024-08-09 13:56:23 -0500 | Rating Details | |
2024-08-09 13:53:21 -0500 | Rating Details | |
2024-08-09 13:42:32 -0500 | Rating Details | |
2024-08-09 13:42:04 -0500 | Rating Details | |
2024-08-09 13:27:41 -0500 | Rating Details | |
2024-08-09 13:16:56 -0500 | Rating Details | |
2024-08-09 13:04:17 -0500 | Rating Details | |
2024-08-09 12:40:55 -0500 | Rating Details | |
2024-08-09 12:31:01 -0500 | Rating Details | |
2024-08-09 12:04:33 -0500 | Rating Details | |
2024-08-09 12:01:40 -0500 | Rating Details | |
2024-08-09 11:54:01 -0500 | Rating Details | |
2024-08-09 11:48:33 -0500 | Rating Details | |
2024-08-09 11:41:16 -0500 | Rating Details | |
2024-08-09 11:36:48 -0500 | Rating Details | |
2024-08-09 11:25:49 -0500 | Rating Details | |
2024-08-09 11:24:09 -0500 | Rating Details | |
2024-08-09 11:19:20 -0500 | Rating Details | |
2024-08-09 11:15:29 -0500 | Rating Details | |
2024-08-09 11:14:52 -0500 | Rating Details | |
2024-08-09 11:14:14 -0500 | Rating Details | |
2024-08-09 11:08:57 -0500 | Rating Details | |
2024-08-09 11:00:43 -0500 | Rating Details | |
2024-08-09 10:56:39 -0500 | Rating Details | |
2024-08-09 10:56:25 -0500 | Rating Details | |
2024-08-09 10:55:05 -0500 | Rating Details | |
2024-08-09 10:53:23 -0500 | Rating Details | |
2024-08-09 10:52:37 -0500 | Rating Details | |
2024-08-09 10:51:05 -0500 | Rating Details | |
2024-08-21 11:54:42 -0500 | Rating Details | |
2024-08-12 06:44:31 -0500 | Rating Details | |
2024-08-10 19:51:25 -0500 | Rating Details | |
2024-08-10 16:27:33 -0500 | Rating Details | |
2024-08-10 16:10:55 -0500 | Rating Details | |
2024-08-10 10:46:05 -0500 | Rating Details | |
2024-08-10 06:35:53 -0500 | Rating Details | |
2024-08-10 05:57:57 -0500 | Rating Details | |
2024-08-10 05:13:40 -0500 | Rating Details | |
2024-08-10 04:58:22 -0500 | Rating Details | |
2024-08-10 04:30:03 -0500 | Rating Details | |
2024-08-10 04:11:52 -0500 | Rating Details | |
2024-08-10 04:10:04 -0500 | Rating Details | |
2024-08-10 04:07:26 -0500 | Rating Details | |
2024-08-10 04:06:25 -0500 | Rating Details | |
2024-08-10 02:37:49 -0500 | Rating Details | |
2024-08-10 01:13:16 -0500 | Rating Details | |
2024-08-09 23:25:56 -0500 | Rating Details | |
2024-08-09 20:43:21 -0500 | Rating Details | |
2024-08-09 19:56:44 -0500 | Rating Details | |
2024-08-09 19:24:09 -0500 | Rating Details | |
2024-08-09 18:46:58 -0500 | Rating Details | |
2024-08-09 16:53:11 -0500 | Rating Details | |
2024-08-09 16:43:24 -0500 | Rating Details | |
2024-08-09 16:07:00 -0500 | Rating Details | |
2024-08-09 15:30:38 -0500 | Rating Details | |
2024-08-09 14:47:59 -0500 | Rating Details | |
2024-08-09 13:27:52 -0500 | Rating Details | |
2024-08-09 11:28:26 -0500 | Rating Details | |
2024-08-09 11:19:51 -0500 | Rating Details | |
2024-08-09 11:16:50 -0500 | Rating Details | |
2024-09-28 17:16:57 -0500 | Rating Details | |
2024-10-13 12:54:45 -0500 | Rating Details |